Coxsackievirus Infections - 24 Studies Found
| Completed |
: A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients : Stage IV Melanoma : 2007-02-19 : Drug: Coxsackievirus A21 Two doses of drug, separated by 48 hours |
| Recruiting |
: Study of Intratumoral CAVATAK™ (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma : Melanoma : 2014-11-26 :
|
| Completed |
: Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma : Malignant Melanoma : 2005-10-07 : Drug: Coxsackievirus A21 |
| Completed |
: Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers :
: 2008-03-07 : Drug: CVA21 IV infusion, dose escalation of one or two infusions of escalating strength |
| Terminated |
: A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients : Head and Neck Cancer : 2009-01-29 : Biological: Coxsackievirus A21 1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals. |
| Recruiting |
: Phase I Study of Intratumoral CAVATAK™ and Pembrolizumab in Subjects With Advanced Melanoma : Melanoma : 2015-09-30 :
|
| Completed |
: A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma : Malignant Melanoma : 2010-10-20 : Biological: Coxsackievirus A21 (CVA21) CVA21 is a live oncolytic virus preparation derived from the non- |
| Completed |
: Efficacy and Safety of Intratumoral CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks : Melanoma : 2012-07-05 : Biological: Coxsackievirus A21 |
| Completed |
: Safety and Clinical Activity of CAVATAK™ Alone or With Low Dose Mitomycin C in Non-muscle Invasive Bladder Cancer : Non-muscle Invasive Bladder Cancer : 2014-12-07 :
|
| Recruiting |
: Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) :
: 2014-01-19 : Biological: CVA21 |